Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDr. Martens Regulatory News (DOCS)

Share Price Information for Dr. Martens (DOCS)

Share Price is delayed by 15 minutes
Get Live Data
71.50    0.50 (0.70%)
Bid:
71.20
Ask:
74.00
Spread: 2.80 (3.933%)
Market Cap: £684.32m
DOCS Live PriceLast checked at - London Stock Exchange

Intraday Dr. Martens Share Chart

Trading Statement

14 Apr 2023 07:00

RNS Number : 1907W
Dr. Martens PLC
14 April 2023
 

14 April 2023

Dr. Martens plc

 

Year-end trading and LA Distribution Centre updates

 

"Full year revenue was up 10% with Q4 up 6%. In constant currency, full year revenue was up 4% with Q4 level with last year. By channel, Q4 growth was driven by strong DTC trading, led by retail growth of 36%, or 28% in constant currency, but this was offset partly by wholesale being behind last year. Within our regions, EMEA DTC accelerated in Q4 while America DTC remained soft. We took decisive action to tackle the operational issues at our LA DC with shipments now back to normal levels. However, costs associated with resolving these issues were higher than our initial estimates which, in conjunction with softer Q4 wholesale revenue, means we expect EBITDA for the year to be around £245m. We continue to adopt a custodian mindset, taking decisions in the best long-term interests of all our stakeholders, and I believe firmly in the DOCS strategy, the continued strength of the Dr. Martens brand and the medium to long-term growth potential of the business. I look forward to sharing more details at the full year results." Kenny Wilson, Chief Executive Officer

 

Performance summary

Q4 revenue was up 6% (flat in constant currency (CC)) driven by strong direct-to-consumer (DTC) growth in EMEA and APAC, offset in part by continued soft DTC in America. Wholesale revenue was down in Q4 due mainly to the LA distribution centre (DC) operational issues and our planned shipment reduction to our China distributor, offset in part by growth in EMEA.

· Q4 total revenue grew 6% (flat CC) driven by strong overall DTC trading, which grew 20% (13% CC), with wholesale down 4% (-11% CC). Within DTC, retail grew 36% (28% CC) and ecommerce grew 8% (2% CC).

· For the full year, revenue growth was 10% (4% CC). DTC was up 16% (11% CC) and wholesale was up 4% (-3% CC). Within DTC, retail was up 30% (25% CC) and ecommerce was up 6% (1% CC).

· We now expect FY23 EBITDA to be around £245m due to higher costs at our LA DC and lower wholesale revenue.

· At 31 March, the company had cash of c.£158m and inventory of c.£258m.

 

LA DC update

We have made good progress on resolving the operational issues at our LA DC, which began impacting our America wholesale channel from December.

· Our most experienced supply chain team were sent to LA to take control of operations and implement the recovery plan, and they remain heavily involved.

· We opened three temporary warehouses to release excess shipping containers and store stock away from the LA DC.

· A third shift was added to focus on the additional work required to unblock the bottleneck and transfer excess stock to the temporary warehouses.

· As a result, shipment volumes at the LA DC are now back to normal levels.

· Work commenced on enlarging and reconfiguring the New Jersey DC to allow it to store, pick and pack for both DTC and wholesale channels in America and, in line with our plans, a successful, initial test shipment took place in March.

· In FY23, total incremental costs associated with the LA DC were c.£15m, higher than the £8-11m expected initially, due mainly to higher than anticipated container costs.

 

FY24

We are maintaining FY24 revenue growth guidance of mid to high single digits on a constant currency basis.

As with FY23, we expect FY24 incremental costs associated with the LA DC will be c.£15m, due mainly to rent annualisation as we now plan to maintain temporary warehouses for the full year, offset partly by lower year-on-year container and handling costs. These costs will be H1 weighted. 

Enquiries

Investors and analysts

Mark Blythman, Interim Director of Investor Relations Mark.Blythman@drmartens.com +44 7570 871207

Beth Callum, Senior Investor Relations Analyst Beth.callum@drmartens.com +44 203 995 2644

 

Press

Maitland +44 207 379 5151

Clinton Manning +44 7711 972662

 

Gill Hammond, Director of Communications +44 7384 214248

 

Investor and analyst conference call

Kenny Wilson, CEO, and Jon Mortimore, CFO, will host a conference call with Q&A for analysts and investors at 0800 BST. This can be accessed via https://www.drmartensplc.com/.

About Dr. Martens

Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Produced originally for workers looking for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical movements. Dr. Martens has since transcended its working-class roots while still celebrating its proud heritage and, six decades later, "Docs" or "DM's" are worn by people around the world who use them as a symbol of empowerment and their own individual attitude. The Company is a constituent of the FTSE 250 index.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTNKNBPCBKDNQD
Date   Source Headline
12th Jul 20233:59 pmRNSDirector/PDMR Shareholding
11th Jul 20231:59 pmRNSHolding(s) in Company
4th Jul 20239:12 amRNSTotal Voting Rights
4th Jul 20239:00 amRNSDirector/PDMR Shareholding
13th Jun 20231:09 pmRNSDirector/PDMR Shareholding
13th Jun 20239:00 amRNSAnnual Financial Report
7th Jun 20234:37 pmRNSNotification of transaction of PCA of PDMR
5th Jun 20234:49 pmRNSDirector/PDMR Shareholding
5th Jun 20233:00 pmRNSDirector/PDMR Shareholding
1st Jun 202312:03 pmRNSBlock listing Interim Review
1st Jun 202311:00 amRNSTotal Voting Rights
1st Jun 20237:00 amRNSFinal Results
17th May 202311:30 amRNSDirector/PDMR Shareholding
2nd May 20233:12 pmRNSTotal Voting Rights
17th Apr 20237:00 amRNSDirector/PDMR Shareholding
14th Apr 20237:01 amRNSCFO retirement
14th Apr 20237:00 amRNSTrading Statement
3rd Apr 20232:54 pmRNSTotal Voting Rights
24th Mar 20237:00 amRNSDirectorate Change
14th Mar 20235:09 pmRNSReplacement Director/PDMR Shareholding
14th Mar 20233:19 pmRNSDirector/PDMR Shareholding
1st Mar 20234:17 pmRNSTotal Voting Rights
15th Feb 20232:16 pmRNSDirector/PDMR Shareholding
6th Feb 20235:30 pmRNSDirector/PDMR Shareholding
1st Feb 202312:12 pmRNSTotal Voting Rights
19th Jan 20237:00 amRNSTrading Statement
13th Jan 20232:11 pmRNSDirector/PDMR Shareholding
3rd Jan 20233:36 pmRNSTotal Voting Rights
14th Dec 20221:35 pmRNSDirector/PDMR Shareholding
1st Dec 20228:38 amRNSTotal Voting Rights
30th Nov 202210:02 amRNSDirector/PDMR Shareholding
24th Nov 20227:00 amRNSHalf-year Report
15th Nov 20223:54 pmRNSBlock listing Interim Review
15th Nov 20223:44 pmRNSDirector/PDMR Shareholding
1st Nov 20227:00 amRNSTotal Voting Rights
1st Sep 20227:00 amRNSTotal Voting Rights
23rd Aug 20222:38 pmRNSDirector/PDMR Shareholding
1st Aug 202211:51 amRNSTotal Voting Rights
14th Jul 202212:33 pmRNSResult of AGM
14th Jul 20227:00 amRNSTrading Statement
6th Jul 20227:00 amRNSConversion Markets - teach-in event
29th Jun 20228:13 amRNSDirector Declaration
16th Jun 202212:16 pmRNSDirector/PDMR Shareholding
14th Jun 20229:00 amRNSAnnual Financial Report
1st Jun 20227:00 amRNSFinal Results
27th Apr 20228:57 amRNSDirector Declaration
1st Apr 20223:18 pmRNSTotal Voting Rights
1st Apr 20222:01 pmRNSBlock listing Interim Review
30th Mar 20227:00 amRNSBlock Listing Application
22nd Mar 20227:43 amRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.